EFFECTIVENESS OF COMPLEX THERAPY OF PATIENTS WITH ACUTE SENSONEURAL OBTUSITY THE EFFICIENCY OF COMPLEX TREATMENT OF PATIENTS WITH ACUTE SENSORINEURAL HEARING LOSS
https://doi.org/10.21518/2079-701X-2017-8-64-67
Abstract
Hearing – one of the most important feelings of a human body. Permanent decrease in hearing against the background of which perception of environmental sounds and speech communication is at a loss, a bradyacuasia is defined by the term. And the problem of a sharp and sudden sensonevralny bradyacuasia is represented to the most composite significant. Can be the reasons of development of sharp violations of sound perception infectious, immunopathological, physical, chemical and ischemichypoxemic factors. Treatment of a sharp and sudden sensonevralny bradyacuasia is considered as rendering an emergency aid. The gold international standard at the present stage is use of glucocorticosteroids. For minimization of the damaging action of causal factors of development of pathological process, improvement of exchange processes, restitution of the functional activity and an angenesis including a neuroepithelium, use of neurotropic therapy-group B vitamins is shown to patients with sharp sensonevralny bradyacuasia. The most efficient are the medicines containing a complex of B1, B6 and B12 vitamins, one of such combined polyvitaminic pharmaceuticals is Neyromultivit.
About the Authors
G. N. Nikiforova
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
MD, Prof.
A. N. Slavskiy
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
PhD in Medicine
V. F. Gergiev
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Бакулина Л.С., Машкова Т.А. Сенсоневральная тугоухость: этиология, терапия и реабилитация. Современные проблемы физиологии и патологии слуха: матер. 2-го Национального конгресса аудиологов и 6-го Международного симпозиума. Суздаль, 2007: 44-45.
2. World Health Organization. Fact Sheet №.300: Deafness and hearing impairment, 2015. Available from: http://www.who.int/mediacentre/factsheets/ fs300/en/
3. Беличева Э.Г. Острая и внезапная сенсоневральная тугоухость: этиология, клиника, диагностика, эффективность ранней этиопатогенетической терапии: Дис. ... д-ра мед. наук: СПб. 2008. 236 c.
4. Загорянская М.Е., Румянцева М.Г. Значение эпидемиологических методов исследования в профилактике нарушения слуха у детей. Рос. оторинолар., 2003, 6(3): 79-83.
5. Иванец И.В. Острая и внезапная нейросенсорная тугоухость (клиникоэкспериментальные исследования): Автореф. дис... д-ра мед. М., 2001. 42 с.
6. Глухота и потеря слуха. Информационный бюллетень ВОЗ. №300. Март 2015 г. http://www.who.int/mediacentre/factsheets/fs300/en/.
7. Hughes GB, Freedman MA, Haberkamp TJ et al. Sudden sensorineural hearing loss. Otolaryngol Clin North Am, 1996, 29(3): 393-404.
8. Fetterman BL, Saunders JE, Luxford WM. Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol, 1996, 17: 529-36.
9. Jaffe B. Clinical studies in sudden deafness. Adv Otorhinolaryngol, 1973, 20: 221-8.
10. Шидловская Т.В. Шидловская Т.Ф. Комплексное лечение сенсоневральной тугоухости. Российская оториноларингология (приложение), 2007: 700-705.
11. Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol, 1977, 86(4 pt 1): 463-480.
12. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss, II: a meta-analysis. Arch Otolaryngol Head Neck Surg, 2007, 133(6): 582-586.
13. Журавский Г. Сенсоневральная тугоухость: молекулярно-генетические, структурные и лечебнопрофилактические аспекты (клинико-экспериментальное исследование): Автореф. дис... д-ра мед.наук. СПб., 2001. 35 с.
14. Пальчун В.Т., Сагалович Б.М. Острая и внезапная нейросенсорная тугоухость. Вестник оторинолар., 1994, 5: 5-12.
15. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: A double-blind clinical study. Arch Otolaryngol, 1980, 106: 772-6.
16. Stokroos RJ, Albers F, Schirm J. The etiology of idiopathic sudden sensorineural hearing loss: experimental herpes simplex virus infection of the inner ear. Am J Otol, 1998, 19: 447-52.
17. Shirwany NA, Seidman MD, Tang W. Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig. Am J Otol, 1998, 19: 230-5.
18. Wei BP, Mubiru S, O’Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev, 2006, 1: CD003998.
19. Labus J, Breil J, Stutzer H, Michel O. Meta-analysis for the effect of medical therapy vs. placebo on recovery of idiopathic sudden hearing loss. Laryngoscope, 2010, 120(9): 1863-1871.
20. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss, I: a systematic review. Arch Otolaryngol Head Neck Surg, 2007, 133(6): 573-581.
21. Slattery WH, Fisher LM, Iqbal Z, Friedman RA, Liu N. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg, 2005, 133(2): 251-259.
22. Megighian D, Bolzan M, Barion U, Nicolai P. Epidemiological considerations in sudden hearing loss: a study of 183 cases. Arch Otorhinolaryngol, 1986, 243(4): 250-253.
23. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope, 1999, 109(7, pt 2): 1-17.
24. Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol, 2005, 26(5): 878-881.
25. Fitzgerald D.C., McGuire J.F. Intratympanic steroids for idiopathic sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol. 2007, 116(4): 253-256.
26. Cvorovic L, Deric D, Probst R, Hegemann S. Prognostic model for predicting hearing recovery in idiopathic sudden sensorineural hearing loss. Otol Neurotol, 2008, 29(4): 464-469.
27. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol, 1978, 13(7): 833-837.
28. Rauch SD. Clinical practice: idiopathic sudden sensorineural hearing loss. N Engl J Med, 2008, 359(8): 833-840.
29. Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs, 1978, 16(3): 238-255.
30. Holland EG, Taylor AT. Glucocorticoids in clinical practice. J Fam Pract, 1991, 32(5): 512-519
31. Nash JJ, Nash AG, Leach ME, Poetker DM. Medical malpractice and corticosteroid use. Otolaryngol Head Neck Surg, 2011, 144(1): 10-15.
32. Alexander TH, Weisman MH, Derebery JM et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol Neurotol, 2009, 30(4): 443-448.
33. Methylprednisolone: drug information. http:// www.uptodate.com/contents/methylprednisolonedrug-information. Accessed May 15, 2011.
34. Saag KG, Furst DE. Major side effects of systemic glucocorticords. http://www.uptodate.com/contents/major-side-effectsof-systemic-glucocorticoids Title=1~150. Accessed May 18, 2011.
35. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol, 2001, 22(1): 18-23.
36. Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol, 2008, 29(4): 453-460.
37. Ahn JH, Yoo MH, Yoon TH, Chung JW. Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness? Laryngoscope, 2008, 118(2): 279-282.
38. Haynes DS, O’Malley M, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 2007, 117(1): 3-15.
39. Nezamoddin Berjis, Saeed Soheilipour, Alireza Musavi, Seyed Mostafa Hashemi. Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Advanced Biomedical Research, 2016, 1-5.
40. Brian DH, Sam JM. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg, 2005, 132: 527-531.
41. Hu A, Parnes LS. Intratympanic steroids for inner ear disorders: a review. Audiol Neurootol, 2009, 14(6): 373-382. Doyle K.J., Bauch C., Battista R., et al. Intratympanic steroid treatment: a review. Otol Neurotol. 2004, 25(6): 1034-1039.
42. Alles MJ, der Gaag MA, Stokroos RJ. Intratympanic steroid therapy for inner ear diseases, a review of the literature. Eur Arch Otorhinolaryngol, 2006, 263(9): 791-797.
43. Hoffer ME, Balough BJ, Gottshall KR. Delivery of drugs to the inner ear. Curr Opin Otolaryngol Head Neck Surg, 2006, 14(5): 329-331.
44. Bettendorff L, Kolb HA, Schoffeniels E. Thiamine triphosphate activates anion channels of large unit conductance in neuroblastoma cells. J. Membr. Biol., 1993, 136: 281-288.
45. Bâ A. Metabolic and structural role of thiamine in nervous tissues. Cell. Mol. Neurobiol., 2008 Nov, 28(7): 923-31.
46. Горбачев В.В., Горбачева В.Н. Витамины, микрои макроэлементы: Справочник. Мн.: Книжный дом: Интерпрессервис, 2002. 544 с.
47. Wilson RG, Davis RE. Clinical chemistry of vitamin B6. Adv. Clin. Chem., 1983, 23: 1-68.
48. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Folate, Vitamin B6, and B12 Intakes in Relation to Risk of Stroke Among Men. Stroke, 2004: 35-169.
49. Diaz DE, Tuesta AM, Ribo MD, Belinchon O, Marchena PJ, Bruscas MJ, Val E, Cortes A, Nieto JA. Low levels of vitamin B 12 and venous thromboembolic disease in elderly men. J. Intern. Med., 2005 Sep, 258(3): 244-9.
50. Киричек Л.Т. Фармакология витаминов. Международный медицинский журнал, 2001, 7(4): 97-104.
51. Нейромультивит. Инструкция по применению: http://www.rlsnet.ru/tn_index_id_1643.htm.
52. Козелкин А.А., Кузнецов А.А., Медведкова С.А. Применение нейромультивита в неврологической практике. Therapia, 2008, 11(31): 1-5.
53. Жиров И.В., Федина М.А., Покровский А.Б. Опыт применения препарата Нейромультивит при алкогольной полинейропатии. Новые лекарственные препараты, 2002, 12: 10-18.
54. Гуревич К.Г. Нейромультивит: применение в современной практике. Фарматека, 2004, 9-10: 48-51.
55. Токмакова А.Ю. Анциферов М.Б. Возможности использования Нейромультивита в комплексной терапии полинейропатии у больных сахарным диабетом. Сахарный диабет, 2001, 11(2): 33-35.
56. Бреговский В.Б., Белогурова Е.В., Кузьмина В.А. Применение Нейромультивита у больных с хронической формой диабетической сенсомоторной полинейропатией нижних конечностей. Новые лекарственные препараты, 2002, 6: 7-10.
57. Шавловская О.А. Витамины группы В в неврологической практике. РМЖ, 2013, 30: 1582-1585.
Review
For citations:
Nikiforova GN, Slavskiy AN, Gergiev VF. EFFECTIVENESS OF COMPLEX THERAPY OF PATIENTS WITH ACUTE SENSONEURAL OBTUSITY THE EFFICIENCY OF COMPLEX TREATMENT OF PATIENTS WITH ACUTE SENSORINEURAL HEARING LOSS. Meditsinskiy sovet = Medical Council. 2017;(8):64-67. (In Russ.) https://doi.org/10.21518/2079-701X-2017-8-64-67
Views:
7970
Email this article 